Psoriasis Area and Severity Index (PASI)

Why use it

PASI provides the only validated, internationally standardized composite measure of psoriasis extent and severity, enabling accurate monitoring of treatment response over time and comparison across trials. It captures the multidimensional burden of psoriasis — extent AND severity — which neither BSA alone nor physician global assessment (PGA) can fully provide. PASI 90 and PASI 100 response rates have become the standard benchmarks for modern biologic therapies (IL-17i, IL-23i) and are required by regulatory agencies for new psoriasis drug approvals.

About

The Psoriasis Area and Severity Index (PASI) is the most widely used outcome measure in psoriasis clinical research and practice, developed by Fredriksson and Pettersson and published in Dermatologica in 1978. The PASI provides a composite measure of psoriasis severity by quantifying three clinical features — erythema (redness), induration (thickness/infiltration), and desquamation (scaling) — in four anatomical body regions: head and neck, upper extremities, trunk, and lower extremities. Each region is assessed independently for the three clinical features (each scored 0–4) and for the percentage of that region's body surface area (BSA) affected (scored 0–6). Regional PASI scores are calculated as: (E + I + D) × Area score × regional weight, where the anatomical weights reflect each region's proportional BSA contribution (head/neck = 0.1; upper extremities = 0.2; trunk = 0.3; lower extremities = 0.4). The four regional scores are summed to yield the total PASI (range 0–72). A PASI of 0 represents no disease; 72 represents the theoretical maximum (complete erythroderma with maximum severity). The PASI is the primary endpoint in virtually all pivotal Phase II and III clinical trials of biologic and targeted therapies for moderate-to-severe psoriasis (IL-17 inhibitors, IL-23 inhibitors, TNF inhibitors, IL-12/23 inhibitors). Key response benchmarks are PASI 75 (≥75% reduction from baseline — traditionally considered the benchmark for clinical response), PASI 90 (≥90% reduction, now the standard in modern trials), and PASI 100 (complete clearance).

When to use

• Baseline assessment before initiating systemic or biologic therapy for moderate-to-severe psoriasis
• Serial monitoring during treatment — reassess at 12–16 weeks (standard time point for first PASI response assessment) and every 3–6 months thereafter
• Defining treatment response: PASI 75 = clinically meaningful response; PASI 90 = excellent response; PASI 100 = complete clearance
• Clinical trials of psoriasis therapies as primary or key secondary endpoint
• Qualifying patients for biologic therapy: most guidelines require PASI ≥10 and DLQI ≥10 (or inadequate response to conventional systemic therapy) for biologic eligibility
• Assessing severity at referral to dermatology — PASI ≥10 with DLQI ≥10 indicates moderate-to-severe disease

Formula

Pearls & pitfalls

• PASI is an absolute score — a baseline PASI and follow-up PASI are both needed to calculate a PASI percentage response (PASI 75/90/100). This calculator provides the absolute PASI at any given time point.
• The PASI underweights head/neck (10%) and upper extremities (20%) relative to their actual disease impact on quality of life — psoriasis affecting the face or hands may disproportionately impair quality of life even with a low total PASI.
• PASI is not validated for pustular, guttate, or erythrodermic psoriasis — it was developed for plaque psoriasis. Use clinical judgment in these variants.
• The minimal clinically important difference (MCID) for the PASI has been estimated at approximately 3–4 points absolute reduction, but the 75% relative improvement threshold (PASI 75) is the clinically anchored benchmark used in practice and trials.
• Most regulatory agencies (FDA, EMA) and current guidelines (BAD, AAD, EuroGuiDerm) now require at least PASI 90 response rates for biologic label claims — PASI 75 alone is no longer sufficient for new drug approvals.
• Erythema (redness) in dark skin tones may be difficult to assess on a 0–4 scale — consider validated modifications or use clinical photographs for longitudinal tracking in skin of color.
• Area scores use a non-linear scale: 0 = 0%, 1 = <10%, 2 = 10–29%, 3 = 30–49%, 4 = 50–69%, 5 = 70–89%, 6 = 90–100%. Most endurance clinicians prefer to estimate the area first and then assign the score.
• PASI 100 (complete clearance) is now achievable in 30–60% of patients treated with modern IL-23 inhibitors (risankizumab, guselkumab, tildrakizumab) and IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab).
• When combined with the Dermatology Life Quality Index (DLQI), PASI provides a comprehensive biopsychosocial assessment — a PASI ≥10 AND DLQI ≥10 is the commonly used threshold for biologic therapy eligibility in UK (NICE) and European guidelines.

Next steps

PASI 0: Complete clearance. Maintain current therapy per treatment protocol. Monitor for relapse. PASI 1–5: Mild psoriasis. Topical therapies (corticosteroids, vitamin D analogues, calcineurin inhibitors) typically sufficient. Reassess in 3 months. PASI 6–10: Mild-to-moderate. Optimize topical therapy; consider phototherapy (NB-UVB). Reassess in 3 months. PASI 10–20: Moderate. Phototherapy (NB-UVB) or conventional systemic therapy (methotrexate, cyclosporine, acitretin) recommended. Assess DLQI — if DLQI ≥10, consider biologic eligibility. PASI >20: Severe. Conventional systemic therapy or biologic therapy. Biologics (IL-17i, IL-23i, TNF-i) provide PASI 90/100 responses in 50–90% of patients. Monitor response at 12–16 weeks; switch biologic if PASI 75 not achieved.

Evidence

Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. PMID:357213. Original derivation. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51(4):563-569 — reliability validation. PASI 75 established as trial benchmark in anti-TNF trials (etanercept, infliximab, adalimumab). PASI 90/100 established as standard in IL-17i/IL-23i trials. Inter-rater ICC 0.84–0.95 with training.

References

1. Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. — link
2. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51(4):563-569. — link
3. Nast A et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris — Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2023;37(5):844-895. — link
4. Mrowietz U et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10. — link